

2'-DEOXYCOFORMYCIN AND OTHER ADENOSINE DEAMINASE INHIBITORS

Robert I. Glazer

*Applied Pharmacology Section
Laboratory of Medicinal Chemistry and Biology
National Cancer Institute
Bethesda, Maryland 20205 USA*

CONTENTS

	Page
ABSTRACT	106
INTRODUCTION	106
ABBREVIATIONS	106
STRUCTURE-ACTIVITY AND KINETIC CHARACTERISTICS	107
POTENTIATION OF 2'-DEOXYADENOSINE AND ADENOSINE TOXICITY	111
POTENTIATION OF ADENOSINE ANALOGS	113
IMMUNOSUPPRESSIVE ACTIVITY	116
DISPOSITION, EXCRETION AND METABOLISM	118
CONCLUSIONS	119
REFERENCES	121

0334-2190/80/010105-128 \$01.00

© 1980 by Freund Publishing House Ltd.

ABSTRACT

A comprehensive review of the pharmacological properties of adenosine deaminase inhibitors and their interaction with adenosine metabolites and analogs is presented. I have concentrated upon the therapeutic utility of this class of drugs, rather than upon their mechanism of action with respect to the kinetics of adenosine deaminase, in the hope that this review will serve as a more useful framework for further drug development in this field, and as a reference for current and future clinical trials.

INTRODUCTION

The search for ADA inhibitors is an area of drug development that has been actively pursued for the past 15 years. The development of the antibiotics, coformycin and dCF, which are stoichiometric tight binding inhibitors, has sparked new interest in this area. These drugs have greatly improved the therapeutic activity, and in some instances, also the therapeutic index of anticancer agents which are adenosine analogs. dCF also possesses lymphocytopenic and immunosuppressive activities. Because of its unusual combination of therapeutic activities, there is at present intense clinical interest in dCF as both a single agent, and in combination with antitumor and antiviral adenosine analogs. On the other hand, aliphatic alcohol analogs of adenine such as EHNA, possess intrinsic antiviral activity, as well as the ability to potentiate the anticancer activity of these analogs.

The recent proliferation of reports concerned with the use of ADA inhibitors in combination with antitumor agents, as well as with adenosine and 2'-deoxyadenosine, has prompted a need for the collation and comparative assessment of these data. In this review I have concentrated upon the pharmacological properties of ADA inhibitors, their use in studying the mechanisms of cytotoxicity of adenosine analogs and their metabolites, and the preliminary pharmacokinetic and clinical findings of these drugs.

ABBREVIATIONS

ADA	adenosine deaminase
dCF	2'-deoxycoformycin
EHNA	erythro-9-(2-hydroxy-3-nonyl)adenine
SAH	S-adenosylhomocysteine

STRUCTURE-ACTIVITY AND KINETIC CHARACTERISTICS

Initially, synthetic analogs of adenosine were found to be weak competitive inhibitors of ADA with an ID_{50} in the range of 10^{-5} to 10^{-4} M /14/. The structure-activity requirements optimal for activity were 6-amino and 9-ribosyl or 9-(2-hydroxyalkyl) functional groups. It was not until the rational design and synthesis of EHNA (Fig. 1) with an ID_{50} of 10^{-8} M that a relatively tightbinding competitive inhibitor became available /5/.

The most potent inhibitors of ADA have evolved from the isolation of natural products. The purification of the antibiotics coformycin and dCF (Fig. 1) by Umezawa's laboratory /6, 7/ and by Parke-Davis investigators /8/, respectively, have provided prototypes of unique tight-binding transition state inhibitors with an ID_{50} of 10^{-8} to 10^{-9} M for coformycin /9, 10/ and 10^{-9} to 10^{-11} M for dCF /11-14/ depending on the molecular species of ADA, and the amount of enzyme present in the assay.

The tetrahedral configuration of the 8-hydroxy group in the diazepine ring moiety of the coformycins resembles the transition state intermediate in the hydrolytic deamination of adenosine (Fig. 2). This unique structure enables them to function as stoichiometric transition state inhibitors, with the ribose and 2'-deoxyribose moieties providing added stabilization of the ADA-coformycin complex /15/.

The first clue that the coformycin-type of ADA inhibitors were of the tight-binding class was provided by Sawa *et al.* /6/. The rate of inhibition by coformycin was found to increase with the length of preincubation to produce a "mixed" type of inhibition. These effects were confirmed and extended in elegant kinetic studies /10, 16/ where it was shown that the extent and rate of inhibition was a dual function of enzyme concentration and length of incubation. The calculated K_i for coformycin with erythrocytic ADA was 2.2×10^{-10} M. Similar kinetic features were evident in subsequent studies with dCF, where the K_i was calculated from the association and dissociation rate constants to be 2.5×10^{-12} M /12/. In contrast, the K_i for EHNA was 1.6×10^{-9} M /12/. The 100- and 1000- fold lower K_i for coformycin and dCF, respectively, vs. EHNA is a direct quantitative result of their correspondingly lower dissociation rate constants. A factor which must also be considered is the recently discovered differential sensitivity of various molecular species of ADA to dCF and EHNA /14/. It was found that the




Fig. 1. Structures of EHNA, coformycin and 2'-deoxycoformycin.




Fig. 2. Deamination of adenosine by adenosine deaminase showing the transition state intermediate.

small molecular weight form of calf intestinal ADA was equally as sensitive to both dCF and EHNA ($ID_{50} = 2 \times 10^{-11} M$), whereas the large molecular weight species, or the crude mixture of ADA was less sensitive to EHNA vs. dCF ($ID_{50} = 1 \times 10^{-7} M$ and $2 \times 10^{-8} M$ for EHNA and dCF, respectively, for the large molecular weight species, and $6 \times 10^{-7} M$ and $2 \times 10^{-8} M$, respectively for the crude enzyme mixture). Striking differences in sensitivity of ADA from various mouse and rat tissues to EHNA *in vitro* have also been noted; however, the reason for this variation was not elucidated with respect to the molecular species of ADA affected /17, 18/.

In vivo studies examining the effect of continuous i.v. infusion of EHNA /18/ and dCF /19/ in mice have yielded striking results. EHNA infused at a dose of 4-40 mg/kg per day for 5 days increased ADA activity in the lung, colon, small intestine, stomach, spleen, liver, and kidney but decreased ADA activity in the thymus. In contrast, dCF infused at a dose of 0.4 mg/kg per day for 5 days severely inhibited ADA activity in the thymus, colon, lung, liver and kidney while not markedly affecting ADA activity in the spleen and small intestine, and elevating ADA activity in the stomach /19/. Interestingly, mice bearing a s.c. transplanted colon tumor showed a greater susceptibility to inhibition of ADA activity by dCF in the spleen, colon, and small intestine /19/. Thus, these results point to the necessity of slowly escalating the dose of dCF in patients with cancer, as well as the possible differences in response to dCF, of reticuloendothelial tissues in normal vs. cancer patients.

The kinetic parameters for inhibition by dCF in intact cells are quite different from cell-free or purified preparations of ADA. The association rate constant for intact erythrocytes or Sarcoma 180 cells was 300-500-fold lower vs. cell-free preparations /20/. This effect is probably the main determinant of the reduced ID_{50} of dCF for intracellular ADA, i.e. 10^{-8} to $10^{-7} M$ /21,22/. On the other hand, the slower dissociation of the dCF-ADA complex in intact cells vs. cell-free preparations /20/ is undoubtedly a function of the rate of turnover of ADA in different cell types. This has recently been suggested by *in vivo* studies with dCF where the 48 hr reactivation of ADA from inhibition by dCF was only 13% in erythrocytes which are anucleate and 80% in L1210 cells which are actively synthesizing mRNA /18, 23/. Additional considerations for the slow reactivation of intracellular ADA from inhibi-

tion by dCF are the varying sensitivities of different molecular species of ADA /14, 24/ and the presence of stabilizing or converting factors associated with ADA /25, 26/.

The specificity of action of dCF and EHNA was studied in mouse lymphoma cells where it was found that high concentration (10^{-5} to 10^{-4} M range) of each drug affected all pathways of purine ribonucleotide synthesis /21/. Adenylate deaminase was also inhibited to a greater extent by dCF ($ID_{50} = 10^{-5}$ M) than by EHNA. Agarwal and Parks /27/ found that coformycin and dCF but not EHNA inhibited muscle adenylate deaminase with a K_i of about 5×10^{-8} M and 2×10^{-8} M, respectively /27/. Recently it was reported that the synthetic nucleotide analog of dCF, dCF-5'-monophosphate, inhibited muscle adenylate deaminase with an ID_{50} of 2×10^{-7} M /28/.

POTENTIATION OF 2'-DEOXYADENOSINE AND ADENOSINE TOXICITY

One of the unique features of dCF is its high specificity for inhibiting only ADA with little, if any, effect on other cellular enzymes at optimal concentrations for inhibiting ADA /21/. Several laboratories have taken advantage of this unique pharmacological activity to study the cytotoxicological and biochemical effects of adenosine and 2'-deoxyadenosine when their deamination was prevented by the presence of dCF or another inhibitor of ADA.

The first indication that inhibition of deamination by adenosine could profoundly modify an intracellular process was reported by Wolberg *et al.* /29/. In the presence of EHNA and exogenous adenosine, the levels of cyclic AMP markedly rose in peritoneal lymphocytes sensitized to mouse ascites leukemia cells. Moreover, cytolysis of ascites cells by the sensitized lymphocytes was blocked by adenosine and this effect was enhanced 2 to 3-fold by the presence of EHNA. Increased elevations of cAMP in the presence of norepinephrine and dCF were also reported to occur in cerebral cortex slices *in vitro* /30/.

The effects of ADA blockade on lymphocyte blastogenesis have been actively pursued since the study by Wolberg /29/ in an attempt to assess the function of ADA in immunodeficiency. Since ADA activity does not increase during lymphocyte transformation /31, 32/, its role is presumably a passive and protective one. It is known that most patients with combined immunodeficiency disease lack or contain low levels of

ADA /24, 33-35/. This recessive trait is expressed by levels of 2'-dATP in the lymphocytes and erythrocytes of these patients that are 5 to 100-fold higher than normal /34, 36/. This genetic error has been mimicked pharmacologically with inhibitors of ADA. EHNA in the presence of adenosine inhibited concanavalin A mediated stimulation of [3 H] leucine incorporation in human peripheral lymphocytes by 50%, but 500 times more EHNA was required to produce the same amount of inhibition of [3 H] thymidine incorporation /37/. In contrast, 2'-deoxyadenosine, but not adenosine, in the presence of 1×10^{-6} M dCF inhibited [3 H] leucine incorporation /38/. These results suggest that a pre-S phase event is associated with 2'-deoxyadenosine toxicity, and not simply inhibition of DNA synthesis, via inhibition of ribonucleoside diphosphate reductase. Conversely, Harrap and Paine /31/ reported that only DNA synthesis in mitogen-stimulated lymphocytes was affected by adenosine and coformycin, while DNA and protein synthesis in L1210 cells were equally affected by the same regimen. Nevertheless, the common denominator in these studies is that the cytotoxicity of adenosine or 2'-deoxyadenosine on lymphocyte blastogenesis or tumor cell growth is markedly potentiated by either EHNA /37, 39, 40/, coformycin /31/ or dCF /38, 39/. Moreover, greater inhibition of lymphocyte transformation is produced by 2'-deoxyadenosine compared with adenosine in the presence of dCF /38,39/ or EHNA /40/.

Ullman *et al.* /41/ showed that in a mouse lymphoma line lacking 2'-deoxyadenosine kinase, the sensitivity of these cells to EHNA was greatly diminished. This suggested that phosphorylation of 2'-deoxyadenosine is required for producing cytotoxicity, as found in the wild type lymphoma cells which produced more than a 10-fold elevation in 2'-dATP in the presence of 10^{-5} M EHNA. In contrast, Hershfield *et al.* /42/ reported that adenosine kinase-deficient human lymphoblasts remained as sensitive as the parent cell line to growth inhibition by adenosine in the presence of EHNA. This apparent divergence in mechanism of action between adenosine and 2'-deoxyadenosine indicates that adenosine-mediated cytotoxicity may be produced via an adenine nucleotide-independent process. The validity of this suggestion was shown in studies where the addition of exogenous adenosine in the presence of coformycin or dCF did not significantly elevate ATP levels in mouse leukemia cells /31, 43, 44/, and mitogen-stimulated lymphocytes /31/, but that 2'-deoxyadenosine in the presence of EHNA /41/, dCF /43/ or coformycin /31/ produced moderate to high elevations of 2'-dATP.

One essential metabolic process which may be directly affected by adenosine is methylation via S-adenosyl-L-methionine (Fig. 3). Kredich and Martin /45/, and Kredich and Hershfield /46/ showed that in the presence of EHNA and L-homocysteine thiolactone, adenosine produced marked toxicity to lymphoma cells, and its effect correlated with the elevation of SAH and inhibition of DNA and RNA methylation. This mechanism for adenosine toxicity is particularly intriguing since the reversibility of SAH hydrolase has been demonstrated *in vivo* /47/. SAH is a potent inhibitor of mRNA methylation and viral multiplication /48, 49/. Interestingly, the adenosine analog, cordycepin (3'-deoxyadenosine) inhibits nuclear RNA methylation quite effectively /50/ and may function via its conversion to 3'-deoxySAH /51/ which is an effective inhibitor of 5'-cap methylation of mRNA /48, 49/. Zimmerman *et al.* /52/ recently reported that human erythrocytes were capable of metabolizing cordycepin to an SAH-like metabolite in the presence of EHNA and homocysteine. Of equal importance was their observation that adenosine and homocysteine in the presence of EHNA could not only elevate SAH levels in lymphocytes but also increase the concentration of cyclic AMP /53/. This is particularly important because elevated levels of both cyclic AMP and SAH could potentially inhibit, perhaps synergistically, normal lymphocyte function.

Alternatively, 2'-deoxyadenosine and adenine arabinoside have recently been reported to function as a tight-binding *suicide* inhibitor of SAH hydrolase causing irreversible inactivation of catalytic activity /54/. Such a phenomenon, if active *in vivo*, could indirectly elevate the intracellular concentrations of SAH, and thus produce impairment of the methylation processes critical for cell growth and viability without invoking the necessity for the conversion of 2'-deoxyadenosine to its nucleotide form (Fig. 3). In recently completed studies, we have not found any evidence that 2'-deoxyadenosine, in the presence of dCF, can affect the intracellular concentration of SAH in L1210 cells although adenosine, homocysteine and dCF markedly elevated SAH levels and arrested the methylation of nuclear RNA (Glazer and Hartman, submitted for publication).

POTENTIATION OF ADENOSINE ANALOGS

The expected synergism of ADA inhibitors with adenosine analogs possessing antitumor activity has been demonstrated in a number of tumor systems. When adenosine analogs were combined with EHNA,




Fig. 3. Pathways for metabolism of S-adenosyl-L-methionine. Interference with hydrolysis of SAH via SAH hydrolase is denoted by the dashed (---) line.

marked synergism with cordycepin and adenine arabinoside was seen in L cells in tissue culture and with the latter drug *in vivo* with Ehrlich ascites cells /55/. More recent experiments with dCF demonstrated marked potentiation by dCF of the cytotoxic effects of cordycepin, xylosyladenine, adenine arabinoside and other adenosine analogs in mouse lymphoid leukemia cells both *in vitro* and *in vivo* /11, 56-61/. It is significant that the combination of dCF and adenine arabinoside prolonged the life span of mice bearing intracerebrally implanted L1210 cells by 50 to 90% whereas either drug alone was inactive /59, 60/. dCF alone did not possess any antitumor activity.

It is presumed that the mechanism of this synergism is the sustained formation of high levels of the active nucleotide metabolite derived from the parent adenosine analog. This phenomenon has been corroborated by chromatography studies employing dCF and adenine arabinoside or xylosyladenine where the 5'-triphosphate accumulates in the presence of dCF /44,62-64/. High levels of the 5'-triphosphate of cordycepin and xylosyladenine would be expected to be markedly cytotoxic, and in fact are inhibitory to nuclear RNA synthesis in L1210 cells /22,65/. The latter effects also quantitatively correlate with the degree of synergism seen with this two-drug combination and the inhibition of cell growth of mouse leukemia cells *in vitro* or the prolongation of life span of mice bearing P388 leukemia /11,58/. Interestingly, the effect of dCF on the inhibitory action of cordycepin on mRNA synthesis in regenerating rat liver, a rapid dividing tissue, is only marginal due to the low level of ADA in this tissue /66/. Plunkett *et al.* /67/ have recently reported that the main determinant of the effect of adenine arabinoside on DNA synthesis in mice bearing P388 leukemia and treated in addition with either EHNA or dCF is the retention of the active metabolite AraATP in the tumor cells. This effect occurred despite the more rapid excretion of EHNA and the less sustained inhibition of ADA by this drug in P388 cells in comparison to dCF /68/. In addition, the rephosphorylation and half life of AraATP in CHO cells was not influenced by the presence of either dCF or EHNA /69/. These data support the conclusion that the primary factor influencing the therapeutic activity of adenosine analogs such as adenine arabinoside when inhibitors of ADA are co-administered is the initial concentration of the active antitumor metabolite, and not the rate of excretion of the ADA inhibitor nor the absolute degree and length of inhibition of ADA in the tumor cell. This hypothesis is supported by the equal synergism that 1×10^{-6} M dCF or EHNA exert on the cytotoxicity of adenine

arabinoside 5'-monophosphate in LI210 cells in culture /61/.

Combinations of ADA inhibitors and adenine arabinoside also show pronounced antiviral activity. In initial investigations, it was reported that dCF and adenine arabinoside markedly inhibited the plaque-forming ability of herpes simplex I and II /70-72/. Similar effects were noted with the combination of adenine arabinoside with coformycin /73/ and EHNA /74/. It is of interest that, whereas dCF alone had no antiviral activity /72, 74/, EHNA inhibited the plaque-forming ability of herpes virus by 50% at 10^{-6} M /74/. The potentiation of the antiviral activity of cordycepin by EHNA also showed a direct correlation with inhibition of total RNA synthesis in the infected HeLa cells /74/, a relationship that also parallels the effect that cordycepin and either dCF /22/ or EHNA /55/ have on mouse ascites tumor and fibroblast cells, respectively.

The antiviral activity of EHNA appears to be a characteristic of adenine analogs with aliphatic alcohol substituents at the 9-position /1/. It has recently been reported that 9-(2,3-dihydroxypropyl) adenine, an inhibitor of ADA, strongly inhibits herpes simplex I and II, as well as the RNA viruses that produce vesicular stomatitis and measles /75/. Other aliphatic alcohol analogs of adenine and guanine also possess antiviral activity /76/, and it will be interesting to see if these newer analogs also have potent inhibitory effects on ADA.

An interesting activity of the adenosine analogs, cordycepin and xylosyladenine, which is potentiated by dCF, is their ability to directly, competitively inhibit the phosphorylation of nuclear proteins via cyclic nucleotide-independent protein kinases /77-79/. dCF potentiates the inhibitory effect of xylosyladenine on the phosphorylation of nonhistone chromosomal proteins in LI210 cells to a greater extent than cordycepin /79/, a result quite opposite to the synergism seen with these drug combinations on RNA synthesis /22, 65/. Since the phosphorylation of nuclear proteins is believed to play an active role in regulating transcription /80/ this synergistic effect of dCF undoubtedly contributes to the overall interference with transcription by these drugs.

IMMUNOSUPPRESSIVE ACTIVITY

As EHNA can be distinguished from dCF by its intrinsic antiviral activity, so can dCF be differentiated by its highly selective immunosuppressive activity which EHNA possesses to a lesser degree. Initial studies of the immunosuppressive effects of dCF used single doses of 0.5 to 1.0 mg/kg daily for four days, which inhibited ADA 80 to 100%

/81/. Inhibition of ADA *in vivo* under these conditions did not impair the mitogen-stimulated blastogenic response *in vitro* of thymocyte or spleen cells from these animals. However, this negative finding can be explained by the dilution of viable cells inhibited by dCF upon subculturing. When dCF is preincubated with lymphocyte cultures for one to three days before addition of the mitogen, it inhibits concanavalin A, phytohemagglutinin and pokeweed mitogen-mediated blastogenesis in human peripheral lymphocytes with an ID_{50} of approximately $1 \times 10^6 M$ /82/. In the latter experiments, blastogenesis was measured by [3H] thymidine incorporation three days after the addition of mitogen. In studies where dCF was added simultaneously with the mitogen to lymphocyte cultures, and blastogenesis was assessed by [3H] leucine incorporation at one day after addition of mitogen, only 15% inhibition was produced by $1 \times 10^{-6} M$ dCF /38/. These studies suggest that the immunosuppressive action of dCF is associated with DNA synthesis or at least some biosynthetic event occurring during S phase.

Immunosuppressive activity by dCF, and to a lesser extent by EHNA, was demonstrated by allograft acceptance of LSTRA tumor cells across the H-2 histocompatibility locus /83, 84/. A single dose of 7.5 to 15 mg/kg of dCF administered 24 hr pretransplant resulted in 53 to 68% allograft acceptance vs. 19% acceptance by a similar regimen of 200 mg/kg of EHNA. Divided doses of 0.25 to 0.5 mg/kg of dCF or 150 mg/kg EHNA daily for six days produced only a 20% and 10% acceptance, respectively. EHNA administered at 10 mg/kg daily for 14 days produced a 60% acceptance rate of mouse pancreatic islet allografts across a non-H-2 histocompatibility barrier /85/. Skin graft survival in mice across a non-H-2 histocompatibility barrier was also markedly prolonged (73 to 83% graft survival) by 18 daily doses of 3.3 and 50 mg/kg of EHNA /86/. Thus, dCF appears to be a more potent immunosuppressive drug against a strong antigenic barrier, whereas EHNA, although not devoid of immunosuppressive activity, appears to be a less effective agent.

The selectivity of dCF for lymphoid cells in mice /87/ has also been confirmed in cancer patients where predominantly lymphocytopenia has been observed /88, 89/.

The biochemical effects of EHNA on nucleotide and RNA synthesis have been examined in phytohemagglutinin-stimulated lymphocytes /90/. At concentrations of $1 \times 10^{-5} M$ which completely inhibit ADA, EHNA inhibited the phosphoribosylpyrophosphate-dependent formation of ATP and ITP from adenine and hypoxanthine, respectively. Ribonucle-

otide pool sizes and RNA synthesis were not affected except at exceedingly high concentrations of 5×10^{-4} M. These results are consonant with the study by Henderson *et al.* /21/ who also found that high concentrations of EHNA, as well as dCF inhibited ribonucleotide biosynthesis in mouse lymphoma cells. It should be noted that these ancillary activities are achieved at concentrations of inhibitor that are 10 to 100-fold greater than necessary to inhibit ADA. They may be related, however, to the immunosuppressive effects of these drugs which are produced only at dosages much greater than that required for inhibiting only ADA.

DISPOSITION, EXCRETION AND METABOLISM

The ADA inhibitor most extensively studied pharmacokinetically has been dCF. The tight-binding characteristics of dCF have permitted the development of a highly specific enzymatic assay which measures the inhibition of ADA in the presence of biological fluids. Employing these techniques, it has been shown that the distribution of dCF follows closely the concentration of ADA in the various tissues of all species of animals studied thus far /13, 18, 91/.

The plasma $t_{1/2}$ for the dCF between rodents and dogs is similar (Table I). dCF is rapidly cleared in the urine, but the rate appears to be much slower in man /88/. The latter effect is explained by the longer plasma $t_{1/2}$ in man which was not predicted by the preclinical data. The recent report by Suling *et al.* /92/ and Plunkett *et al.* /68/ suggests that the duration of action of EHNA is approximately 50% of dCF as judged by their respective effects on increasing the $t_{1/2}$ of adenine arabinoside in the plasma /92/ and ascites fluid /68/ in mice. Approximately 50% of an i.v. dose of 5 mg/kg of EHNA was cleared from the plasma in one hour in the Rhesus monkey /93/.

TABLE I Urinary Excretion and Plasma $t_{1/2}$ for dCF.

Species	Plasma $t_{1/2}$ (min)		% Recovered unchanged in urine in 24 hr	Ref.
	α phase	β phase		
Mouse	17-19	64-104	100	91
Rat	-	-	80	13
Dog	12-15	90-120	77	18
Man	45-90	240-360	34	88

The total cumulative excretion of dCF in the urine and feces was 90 to 100% of the administered dose of dCF /13, 18, 91/. Recently, studies of the metabolism of dCF in L1210 cells *in vitro* have demonstrated that only 10 to 15% of the drug (10^{-6} – 10^{-4} M) is converted to the nucleoside monophosphate in 1 to 2 hours, but not further anabolized /94/. This is in contrast to the report by Muller *et al.* /44/ that in mouse L5178Y leukemia cells in culture, 54% of 1×10^{-6} M coformycin is recovered as mono-, di-, and triphosphates upon exposure to the drug for 24 hours. EHNA is almost completely metabolized in mice with numerous hydroxylated metabolites of the aliphatic hydrocarbon moiety being present in the urine after i.v. administration /95/. This finding has been confirmed in the Rhesus monkey where 70% of the administered i.v. doses was eliminated in the urine after 6 hours almost entirely as four metabolites /93/.

CONCLUSIONS

This review has emphasized the pharmacological activities of ADA inhibitors, both as single agents and in combination chemotherapy. The two most studied drugs, EHNA and dCF, each have some unique attributes which should allow them to be further developed on their own merits for clinical trials. Both drugs produce little or no effects on other processes associated with *de novo* purine synthesis or adenine nucleotide catabolism at concentrations which completely inhibit ADA; however, at 100-fold higher concentrations, EHNA appears less specific with respect to its site of action than does dCF /21/.

EHNA possesses antiviral activity which dCF does not, and thus would be expected to be more efficacious in combination with antiviral adenosine analogs in the chemotherapy of acute viral infections. The development of closely related aliphatic alcohol analogs of adenine with potent antiviral activity attests to the unique properties of this structural class of drugs. On the other hand, dCF would be more advantageous for the chemotherapeutic treatment of cancer in combination with adenosine analogs, or quite possibly as a single agent in lymphoid leukemias. The longer half life of dCF and its more prolonged and potent inhibitory effects on ADA vs. EHNA would be a particularly favorable pharmacological property for the chronic treatment of cancer patients. The intrinsic immunosuppressive activity of dCF at higher doses is an added feature of this drug. It may serve as a prototype for a new class of

immunosuppressive agents lacking many of the unfavorable side effects of the current modalities of immunosuppressive therapy.

From an experimentalist's perspective, the use of ADA inhibitors has helped enormously in understanding the mechanism of action of adenosine metabolites and analogs whose catabolism was heretofore neglected with respect to their specificities of action. ADA inhibitors have also enabled us to understand the regulatory processes associated with immunodeficiencies which are characterized by a lack of ADA, and to further understand the maturation of the immune response.

REFERENCES

1. SCHAEFFER, H.J. and BHARGAVA, P.S. Enzyme inhibitors V. The syntheses of 6-substituted-(9-hydroxyalkyl)-purines and their evaluation as inhibitors of adenosine deaminase. *Biochemistry*, 4, 71 (1965).
2. CORY, J.G. and SUHADOLNIK, R.J. Structural requirements of nucleosides for binding by adenosine deaminase. *Biochemistry*, 4, 1729 (1965).
3. FREDERIKSEN, S. Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine analogues. *Arch. Biochem. Biophys.*, 113, 383 (1966).
4. YORK, J.L. and LePAGE, G.A. A kinetic study of the deamination of some adenosine analogues. Substrate specificity of adenosine deaminase. *Can. J. Biochem.*, 44, 331 (1966).
5. SCHAEFFER, H.J. and SCHWENDER, C.F. Enzyme inhibitors 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. *J. Med. Chem.*, 17, 6 (1974).
6. SAWA, T., TUKAGAWA, T., HOMMA, I., TAKEUCHI, T. and UMEZAWA, H. Mode of inhibition of coformycin on adenosine deaminase. *J. Antibiotics A*, 20, 227 (1967).
7. NAKAMURA, H., KOYAMA, G., IITAKA, Y., ONO, M., YAGISAWA, N., KONDO, S., MAEDA, K. and UMEZAWA, H. Structure of coformycin, an unusual nucleoside of microbial origin. *J. Am. Chem. Soc.*, 96, 4327 (1974).
8. WOOD, P.W.K., DION, H.W., LANGE, S.M., DAHL, L.F. and DURHAM, L. J. A novel adenosine and ara-A deaminase inhibitor, (R)-3-deoxy- β -D-erythro-pentofuranosyl]3,6,7,8-tetrahydroimidazo[4,5-d] diazepin-8-ol. *J. Hetero. Chem.*, 11, 641 (1974).
9. AGARWAL, R.P., SAGAR, S.M. and PARKS, Jr. R.E. Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs. *Biochem. Pharmacol.*, 24, 693 (1975).
10. CHA, S. Tight-binding inhibitors III. A new approach for the determination of competition between tight-binding inhibitors and substrates-inhibition of adenosine deaminase by coformycin. *Biochem. Pharmacol.*, 25, 2695 (1976).
11. JOHNS, D.G. and ADAMSON, R.E. Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycorformycin. *Biochem. Pharmacol.*, 25, 1441 (1976).
12. AGARWAL, R.P., SPECTOR, T., PARKS, Jr. R.E. Tight-binding inhibitors IV. Inhibition of adenosine deaminases by various inhibitors. *Biochem. Pharmacol.*, 26, 359 (1977).
13. BORONDY, P.E., CHANG, T., MASCHEWSKE, E. and GLASKO, A.J. Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine). *Ann. N.Y. Acad. Sci.*, 284, 9 (1977).
14. CONSTINE, J., GLAZER, R.I. and JOHNS, D.G. Adenosine deaminase inhibi-

- tors: differential effects on multiple forms of adenosine deaminase. *Biochem Biophys. Res. Commun.*, 85, 198 (1978).
15. WOLFENDEN, R., WENTWORTH, D.F. and MITCHELL, G.N. Influence of substituent ribose on transition state affinity in reactions catalyzed by adenosine deaminase. *Biochemistry*, 16, 5071 (1978).
 16. CHA, S., AGARWAL, R.P. and PARKS, Jr. R.E. Tight-binding inhibitors II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. *Biochem. Pharmacol.*, 24, 2187 (1975).
 17. TROTTA, P.P., ASHLAND, M.P., BROWN, G.F. and BALIS, M.E. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase. *Mol. Pharmacol.*, 14, 199 (1978).
 18. CHASSIN, M.M., ADAMSON, R.H., ZAHAREVITZ, D.W. and JOHNS, D.G. Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats. *Biochem. Pharmacol.*, 28, 1849 (1979).
 19. TEDDE, A., BALIS, M.E., SCHONBERG, R. and TROTTA, P.P. Effects of 2'-deoxycoformycin infusion on mouse adenosine deaminase. *Cancer Res.*, 39, 3044 (1979).
 20. ROGLER-BROWN, T., AGARWAL, R.P. and PARKS, Jr. R.E. Tight-binding inhibitors VI. Interactions of deoxycoformycin and adenosine deaminase in intact human erythrocytes and sarcoma 180 cells. *Biochem. Pharmacol.*, 27, 2289 (1978).
 21. HENDERSON, J.F., BROX, L., ZOMBOR, G., HUNTING, D. and LOMAX, C.A. Specificity of adenosine deaminase inhibitors. *Biochem. Pharmacol.*, 26, 1967 (1977).
 22. GLAZER, R.I., LOTT, T.J. and PEALE, A.L. Potentiation by 2'-deoxycoformycin of the inhibitory effect of 3'-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells *in vitro*. *Cancer Res.*, 38, 2233 (1978).
 23. AGARWAL, R.P. Recovery of 2'-deoxycoformycin-inhibited adenosine deaminase mouse erythrocytes and leukemia L1210 *in vivo*. *Cancer Res.*, 39, 1425 (1979).
 24. SCHRADER, W.P., POLLARA, B., MEUWISSEN, H.J. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. *Proc. Nat. Acad. Sci. U.S.A.* 75, 446 (1978).
 25. TROTTA, P.P. and BALIS, M.E. Characterization of adenosine deaminase from normal colon and colon tumors. Evidence for tumor-specific variants. *Biochemistry*, 17, 270 (1978).
 26. DADONNA, P.E. and KELLEY, W.N. Human deaminase binding protein. Assay, purification and properties. *J. Biol. Chem.*, 253, 4617 (1978).

27. AGARWAL, R.P., PARKS, Jr. R.E. Potent inhibition of muscle 5'-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin. *Biochem. Pharmacol.*, 26, 663 (1977).
28. FRIEDEN, C., GILBERT, H.R., MILLER, W.H. and MILLER, R.L. Adenylate deaminase: potent inhibition by 2'-deoxycoformycin 5'-phosphate. *Biochem. Biophys. Res. Commun.*, 91, 278 (1979).
29. WOLBERG, G., ZIMMERMAN, T.P., HIEMSTRA, K., WINSTON, M. and CHU, L.C. Adenosine inhibition of lymphocyte-mediated cytotoxicity: possible role of cyclic adenosine monophosphate. *Science*, 187, 957 (1975).
30. SKOLNICK, P., NIMITKIPAIAN, Y., STALVEY, L. and DALY, J.W. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine. *J. Neurochem.*, 30, 1579 (1978).
31. HARRAP, K.R. and PAINE, R.M. Adenosine metabolism in cultured lymphoid cells. *Advan. Enzyme Regul.*, 15, 169 (1977).
32. RAIVIO, K.O. and HOVI, T. Purine reutilization in phytohemagglutinin-stimulated human T lymphocytes. *Exp. Cell Res.*, 116, 75 (1978).
33. VanDer WEYDEN, M.B., BUCKLEY, R.H. and KELLEY, W.N. Molecular form of adenosine deaminase in severe combined immunodeficiency. *Biochem. Biophys. Res. Commun.*, 57, 590 (1974).
34. COLEMAN, M.S., DONOFRIO, J., HUTTON, J.J., HAHN, L., DAOUD, A., LAMPKIN, B. and DYMINSKI, J. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. *J. Biol. Chem.*, 253, 1619 (1978).
35. HIRSCHHORN, R. Adenosine deaminase deficiency and immunodeficiencies. *Fed. Proc.*, 36, 2166 (1977).
36. DONOFRIO, J., COLEMAN, M.S., HUTTON, J.J., DAOUD, A., LAMPKIN, B., and DYMINSKI, J. Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease. *J. Clin. Invest.*, 62, 884 (1978).
37. CARSON, D.A. and SEEGMILLER, J.E. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. *J. Clin. Invest.*, 57, 274 (1976).
38. UBERTI, J., LIGHTBODY, J.J. and JOHNSON, R.M. The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation. *J. Immunol.*, 123, 189 (1979).
39. LAPI, L. and COHEN, S. Toxicities of adenosine and 2'-deoxyadenosine in L cells treated with inhibitors of adenosine deaminase. *Biochem. Pharmacol.*, 26, 71 (1977).
40. SIMMONDS, H.A., PANAYI, G.S. and CORRIGALL, V. A role of purine metabolism in the immune response: adenosine deaminase activity and deoxyadenosine catabolism. *Lancet*, 1, 60 (1978).

41. ULLMAN, B., GUDAS, L.J., COHEN, A. and MARTIN, Jr. D.W. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. *Cell*, 4, 365 (1978).
42. HERSHFELD, M.S., SNYDER, F.F. and SEEGMILLER, J.E. Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes. *Science*, 197, 1284 (1977).
43. LOWE, J.K., GOWANS, B. and BROX, L. Deoxyadenosine metabolism and toxicity in cultured L5178Y cells. *Cancer Res.*, 37, 3013 (1977).
44. MÜLLER, W.E.G., ZAHN, R.K., ARENDES, J., MAIDHOF, A. and UMEZAWA, H. Influence of coformycin on the cytostatic activity of 9- β -D-arabino-furanosyladenine and adenosine in mouse L5178Y cells. *Hoppe-Seyler's Z. Physiol. Chem.*, 359, 1287 (1978).
45. KREDICH, N.M. and MARTIN, Jr. D.W. Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cells. *Cell*, 12, 931 (1977).
46. KREDICH, N.M. and HERSHFELD, M.S. S-Adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. *Proc. Nat. Acad. Sci., U.S.A.* 76, 2450 (1979).
47. HOFFMAN, J.L. Biosynthesis of S-N⁶-methyl-adenosylhomocysteine, an inhibitor of RNA methyltransferase. *J. Biol. Chem.*, 253, 2905 (1978).
48. PUGH, C.S.G., BORCHARDT, R.T. and STONE, H.O. Inhibition of Newcastle disease virion messenger RNA-(guanine-7)-methyltransferase by analogues of S-adenosylhomocysteine. *Biochemistry*, 16, 3928 (1977).
49. PUGH, C.S.G., BORCHARDT, R.T. and STONE, H.O. Sinefungin, a potent inhibitor of virion mRNA(guanine-7)-methyltransferase, mRNA-(nucleoside-2'-)-methyltransferase, and viral multiplication. *J. Biol. Chem.*, 253, 4075 (1978).
50. GLAZER, R.I. and PEALE, A.L. Cordycepin and xylosyladenine: inhibitors of methylation of nuclear RNA. *Biochem. Biophys. Res. Commun.*, 81, 521 (1978).
51. GLAZER, R.I. and PEALE, A.L. Evidence that xylosyladenine affects methylation by inhibition of S-adenosyl-L-methionine synthesis. *Cancer Letters*, 6, 193 (1979).
52. ZIMMERMAN, T.P., DEEPROSE, R.D., WOLBERG, G. and DUNCAN, G.S. Metabolic formation of nucleoside-modified analogues of S-adenosylmethionine. *Biochem. Biophys. Res. Commun.*, 91, 997 (1979).
53. ZIMMERMAN, T.P., DEEPROSE, R.D., WOLBERG, G. and DUNCAN, G.S. Potentiation by homocysteine of adenosine-stimulated elevation of cellular adenosine 3',5'-monophosphate. *Biochem. Pharmacol.*, 28, 2375 (1979).
54. HERSHFELD, M.S. Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. *J. Biol. Chem.*, 254, 22 (1979).

55. PLUNKETT, W. and COHEN, S.S. Two approaches that increase the activity of analogs of adenine nucleosides in animals cells. *Cancer Res.*, 35, 1547 (1975).
56. LePAGE, G.A., WORTH, L.S. and KIMBALL, A.P. Enhancement of the anti-tumor activity of arabinofuranosyladenine by 2'-deoxycoformycin. *Cancer Res.*, 36, 1481 (1976).
57. CASS, C.E. and AU-YUENG, T.H. Enhancement of 9- β -D-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 *in vitro* by 2'-deoxycoformycin. *Cancer Res.*, 36, 1486 (1976).
58. ADAMSON, R.H., ZAHAREVITZ, D.W., and JOHNS, D.G. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin. *Pharmacology*, 15, 84, (1977).
59. LEE, S.H., CARON, N., and KIMBALL, A.P. Therapeutic effects of 9- β -D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia. *Cancer Res.*, 37, 1953 (1977).
60. CARON, N., LEE, S.H. and KIMBALL, A.P. Effects of 2'-deoxycoformycin, 9- β -D-arabinofuranosyladenine 5'-phosphate, and 1- β -D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia L1210. *Cancer Res.*, 37, 3274 (1977).
61. CASS, C.E., TAN, T.H. and SELNER, M. Antiproliferative effect of 9- β -D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture. *Cancer Res.*, 39, 1563 (1979).
62. CHANG, T. and GLAZKO, A.J. Effect of an adenosine deaminase inhibitor on the uptake and metabolism of arabinosyl adenine (vidarabine) by intact human erythrocytes. *Res. Commun. Chem. Pathol. Pharmacol.*, 14, 127 (1976).
63. ROSE, L.M. and BROCKMAN, R.W. Analysis by high-pressure liquid chromatography of 9- β -D-arabinofuranosyladenine 5'-triphosphate levels in murine leukemia cells. *J. Chromatog.*, 133, 335 (1977).
64. PLUNKETT, W. The use of high-pressure liquid chromatography in research on purine nucleoside analogs. *Advan. Chromatog.*, 16, 211 (1978).
65. PEALE, A.L. and GLAZER, R.I. Potentiation by 2'-deoxycoformycin of the inhibitory effect of xylosyladenine on nuclear RNA synthesis in L1210 cells *in vitro*. *Biochem. Pharmacol.*, 27, 2543 (1978).
66. GLAZER, R.I. The effects of 2'-deoxycoformycin on the action of cordycepin on nuclear RNA synthesis in regenerating liver. *Toxicol. Appl. Pharmacol.*, 46, 191 (1978).
67. PLUNKETT, W., ALEXANDER, L., CHUBB, S. and LOO, T.L. Biochemical basis of the increased activity of 9- β -D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase. *Cancer Res.*, 39, 3655 (1979).

68. PLUNKETT, W., ALEXANDER, L., CHUBB, S. and LOO, T.L. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)-adenine *in vivo*. *Biochem. Pharmacol.*, 28, 201 (1979).
69. SHEWACH, D.S. and PLUNKETT, W. Effect of 2'-deoxycoformycin on the biologic half life of 9- β -D-arabinofuranosyladenine 5'-triphosphate in CHO cells. *Biochem. Pharmacol.*, 28, 2401 (1979).
70. BRYSON, Y., CONNOR, J.D., SWEETMAN, L., COREY, S., STUCKEY, M.A. and BUCHANAN, R. Determination of plaque inhibitory activity of adenine arabinoside (9- β -D-arabinofuranosyladenine) for herpes viruses using an adenosine deaminase inhibitor. *Antimicrob. Agents Chemother.*, 6, 98 (1974).
71. WILLIAMS, B.B. and LERNER, A.M. Antiviral activity of an adenosine deaminase inhibitor: decreased replication of herpes simplex virus. *J. Infect. Dis.*, 131, 673 (1975).
72. SLOAN, B.J., KIELTY, J.K. and MILLER, F.A. Effect of a novel adenosine deaminase inhibitor (Co-vidarabine, Co-V) upon the antiviral activity *in vitro* and *in vivo* of Vidarabine (Vira-A) for DNA virus replication. *Ann. N.Y. Acad. Sci.*, 284, 60 (1977).
73. SMITH, S.H., SHIPMAN, Jr. C. and BRACH, J.C. Deoxyadenosine antagonism of the antiviral activity of 9- β -D-arabinofuranosyladenine and 9- β -D-arabinofuranosylhypoxanthine. *Cancer Res.*, 38, 1916 (1978).
74. NORTH, T.W. and COHEN, S.S. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. *Proc. Nat. Acad. Sci. U.S.A.* 75, 4684 (1978).
75. DeCLERQ, E., DESCAMPS, J. and DeSOMER, R. (S)-9-(2,3-dihydroxypropyl) adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. *Science*, 200, 563 (1978).
76. DeCLERQ, E. and TORRENCE, P.F. Nucleoside analogs with selective antiviral activity. *J. Carbohy. Nucleos. Nucleot.*, 5, 187 (1978).
77. GLAZER, R.I. and KUO, J.F. Inhibitory effects of cordycepin on cyclic nucleotide-dependent and cyclic nucleotide-independent protein kinases. *Biochem. Pharmacol.*, 26, 1287 (1977).
78. LEGRAVEREND, M. and GLAZER, R.I. Inhibition of the phosphorylation of non-histone chromosomal proteins of rat liver by cordycepin and cordycepin triphosphate. *Cancer Res.*, 38, 1142 (1978).
79. LEGRAVEREND, M. and GLAZER, R.I. Inhibition of the phosphorylation of nonhistone chromosomal proteins by cordycepin and xylosyladenine in L1210 cells *in vitro*. *Mol. Pharmacol.*, 14, 1130 (1978).
80. STEIN, G., STEIN, J.L., KLEINSMITH, L.J., THOMSON, J.A., PARK, W.D. and JANSING, R.L. Role of nonhistone chromosomal proteins in the regulation of histone gene expression. *Cancer Res.*, 36, 4307 (1976).
81. BURRIDGE, P.W. PAETKAU, V. and HENDERSON, J.F. Studies of the relationship between adenosine deaminase and immune function. *J. Immunol.*, 119, 675 (1977).

82. CHASSIN, M.M., LOUIE A.C., CHIRIGOS, M.A., ADAMSON, R.H. and JOHNS, D.G. Immune dysfunction produced by the adenosine deaminase inhibitor 2'-deoxycoformycin, *Clin. Res.*, 26, 513A (1978).
83. CHASSIN, M.M., CHIRIGOS, M.A., JOHNS, D.G., ADAMSON, R.H. Adenosine deaminase inhibition for immunosuppression. *New Engl. J. Med.*, 296, 1232 (1977).
84. ADAMSON, R.H., CHASSIN, M.M., CHIRIGOS, M.A. and JOHNS, D.G. Some aspects of the pharmacology of the adenosine deaminase inhibitors 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine. *Current Chemother.*, 11, 1116 (1978).
85. LUM, C.T., SUTHERLAND, D.E.R., ECKHARDT, J., MATAS, A.J. and NAJARIAN, J.S. Effect of an adenosine deaminase inhibitor on survival of mouse pancreatic islet allografts. *Transplantation*, 27, 355 (1979).
86. LUM, C.T., SUTHERLAND, D.E.R. and NAJARIAN, J.S. Inhibition for immunosuppression. *New Engl. J. Med.*, 296, 819 (1977).
87. SMYTH, J.F., YOUNG, R.C. and YOUNG, D.M. *In vivo* toxicity to lymphoid tissue by 2'-deoxycoformycin. *Cancer Chemother. Pharmacol.*, 1, 49 (1978).
88. SMYTH, J.F., CHASSIN, M.M., HARRAP, K.R., ADAMSON, R.H. and JOHNS, D.G. 2'-Deoxycoformycin: Phase I trial and clinical pharmacology. *Proc. Amer. Assoc. Cancer Res.*, 20, 47 (1979).
89. KOLLER, C.A., MITCHELL, B.S., GREVER, M.R., MEJIAS, E., MAL-SPEIS, L. and METZ, E.N. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. *Cancer Treat. Rep.*, 63, 1149 (1980).
90. SKUPP, S., VUGREK, G. and AYVAZIAN, J.H. Effect of erythro-9-(2-hydroxy-3-nonyl)adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutinin-mediated blastogenesis. *Biochem. Pharmacol.*, 28, 3323 (1979).
91. McCONNELL, W.R., SULING, W., RICE, L.S., SHANNON, W.M. and HILL, D.L. Use of microbiologic and enzymatic assays in studies on the disposition of 2'-deoxycoformycin in the mouse. *Cancer Treat. Rep.*, 62, 1153 (1978).
92. SULING, W.J., RICE, L.S. and SHANNON, W.M. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine on plasma levels and urinary excretion of 9- β -D-arabinofuranosyladenine in the mouse. *Cancer Treat. Rep.*, 62, 369 (1978).
93. McCONNELL, W.R., EL DAREER, S.M. and HILL, D.L. Metabolism and disposition of erythro-9-(2-hydroxy-3-nonyl)[^{14}C] adenine in the Rhesus monkey. *Drug Metab. Dispos.*, 8, 5 (1980).
94. VENNER, P.M. and GLAZER, R.I. The metabolism of 2'-deoxycoformycin by L1210 cells *in vitro*. *Biochem. Pharmacol.*, 28, 3239 (1979).

95. LAMBE, C., BUGGE, C.J., LaFON, S.W., NELSON, D.J. and ELION, G.B.
Inhibition of adenosine deaminase *in vivo* in CBA-J mice by erythro-9-(2-hydroxy-3-nonyl)adenine and its metabolic consequences. Fed. Proc., **38**, 670 (1979).